Genomics CEO Says Vertex R&D Pact, £25m Series B Secure Its Viability
The Oxford biotech raised £25m from investors and inked a collaboration with Vertex that's probably worth tens of millions of pounds, maybe much more. The founder and CEO of Genomics PLC tells Scrip the four-year-old company will also seek other pharma alliances.
You may also be interested in...
Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.